Reuters logo
2 个月前
BRIEF-Vericel receives FDA regenerative medicine advanced therapy designation for Ixmyelocel-T
2017年5月10日 / 上午11点20分 / 2 个月前

BRIEF-Vericel receives FDA regenerative medicine advanced therapy designation for Ixmyelocel-T

1 分钟阅读

May 10 (Reuters) - Vericel Corp

* Vericel receives FDA regenerative medicine advanced therapy (RMAT) designation for Ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below